The Group has three reportable segments, as discussed below, which are based on information provided to the Board of Directors, which is deemed to be the Group's chief operating decision maker. Several operating segments which have similar economic characteristics have been aggregated into the reporting segments.

The European Pharmaceuticals Segment comprises Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing. This Segment operates internationally and manufactures and markets Companion Animal, Equine and Food producing Animal Products. This Segment also includes third party manufacturing sales.

The North American (NA) Pharmaceuticals Segment consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, which sell Companion Animal and Equine Products into those territories. The Segment expanded during the prior year with the acquisition of PSPC Inc.'s manufacturing unit based in Melbourne, Florida, and during the current year with the opening of the Canadian subsidiary.

The Pharmaceuticals Research and Development Segment includes all of the Group's pharmaceutical research and development activities. From a Board perspective, this Segment has no revenue income.

Reconciliations of reportable segment revenues, profit or loss and liabilities and other material items:

2015
£000
2014
£000
Revenue by segment
European Pharmaceuticals — total168,665172,449
— inter segment(32)(35)
NA Pharmaceuticals           — total34,87021,215
— inter segment(23)(58)
203,480193,571
Operating profit/(loss) by segment
European Pharmaceuticals48,03049,016
NA Pharmaceuticals10,6375,980
Pharmaceuticals Research and Development(8,671)(8,248)
Segment operating profit49,99646,748
Corporate and other unallocated costs(5,645)(4,580)
Underlying operating profit44,35142,168
Amortisation of acquired intangibles(17,871)(16,543)
Rationalisation costs(9)(479)
Acquisition costs(491)(150)
Total operating profit25,98024,996
Finance income2,242302
Finance expense(2,416)(3,856)
Profit before taxation — continuing operations25,80621,442
Total liabilities by segment
European Pharmaceuticals(24,567)(23,615)
NA Pharmaceuticals(11,486)(8,884)
Pharmaceuticals Research and Development(710)(633)
Segment liabilities(36,763)(33,132)
Corporate loans and revolving credit facility(32,519)(31,653)
Corporate accruals and other payables(3,410)(3,222)
Current and deferred tax liabilities(24,950)(27,961)
(97,642)(95,968)
Revenue by product categoryRestated*
CAP113,88898,155
Equine17,04015,251
FAP27,27833,791
Diets25,57528,372
Third party manufacturing19,69918,002
203,480193,571
Additions to intangible non-current assets by segment (including through business combinations)
European Pharmaceuticals8021,356
NA Pharmaceuticals7,567
Pharmaceuticals Research and Development4221,065
Corporate and central costs45425
1,67810,013

*The prior year categorisation has been restated to reflect the current portfolio, following a product allocation review in the period.

2015
£000
2014
£000
Additions to Property, Plant and Equipment by segment (including through business combinations)
European Pharmaceuticals1,6882,979
NA Pharmaceuticals2142,185
Pharmaceuticals Research and Development10255
Corporate and central costs7726
2,0815,245
Depreciation and amortisation by segment
European Pharmaceuticals17,15617,684
NA Pharmaceuticals3,8281,987
Pharmaceuticals Research and Development497816
Corporate and central costs5750
21,53820,537

Geographical Information

The following table shows revenue based on the geographical location of customers and non-current assets based on the country of domicile of the entity holding the asset:

2015
Revenue
£000
2015
Non-
current
assets
£000
2014
Revenue
£000
2014
Non-
current
assets
£000
UK59,67317,36849,41217,752
Germany34,0521,98338,5992,260
Rest of Europe65,796123,80371,918152,158
USA32,84840,35221,24242,270
Rest of World11,11112,400
203,480183,506193,571214,440